

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

3 ~~The~~A pharmaceutical composition ~~of claim 1, wherein the compound is represented~~comprising a pharmaceutically acceptable excipient and a compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

4. ~~The~~A pharmaceutical composition ~~of claim 2, wherein the~~comprising a pharmaceutically acceptable excipient and a compound ~~is~~ represented by the formula:



or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition for use in treating or preventing a viral infection in a patient, wherein the composition comprises a pharmaceutically effective amount of a compound represented by the formula:



or a pharmaceutically acceptable salt thereof.


6. The pharmaceutical composition of claim 5, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

7. The pharmaceutical composition of claim 5 or claim 6, wherein the viral infection is caused by a human coronavirus

8. The pharmaceutical composition of any of claims 5-7, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

9. The pharmaceutical composition of any of claims 5-8, wherein the viral infection is caused by a SARS coronavirus.

10. A pharmaceutical composition for use in treating or preventing a viral infection, wherein the composition comprises a pharmaceutically effective amount of a compound represented by the formula:



or a pharmaceutically acceptable salt thereof.


11. The pharmaceutical composition of claim 10, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

12. The pharmaceutical composition of claim 10 or claim 11, wherein the viral infection is caused by a human coronavirus

13. The pharmaceutical composition of any of claims 10-12, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

14. The pharmaceutical composition of any of claims 10-13, wherein the viral infection is caused by a SARS coronavirus.

15. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in treating or preventing a viral infection in a patient.


16. The compound of claim 15, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

17. The compound of claim 15 or claim 16, wherein the viral infection is caused by a human coronavirus

18. The compound of any of claims 15-17, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

19. The compound of any of claims 15-18, wherein the viral infection is caused by a SARS coronavirus.


20. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in treating or preventing a viral infection in a patient.


21. The compound of claim 20, wherein the patient is a human.

22. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

23. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

24. The compound of claim 22, represented by the formula:




.

25. The compound of claim 22, wherein the compound is a pharmaceutically acceptable salt of



.

26. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in the treatment of a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.


27. The compound of claim 26, wherein the viral infection is caused by a human coronavirus

28. The compound of claim 26 or claim 27, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

29. The compound of any of claims 26-28, wherein the viral infection is caused by a SARS coronavirus.


30. The compound of any one of claims 26-29, wherein the patient in need thereof is human.

31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically acceptable salt of a compound represented by the formula:




.

32. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:



.


33. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in the treatment of a human coronavirus infection in a patient in need thereof.

34. The compound of claim 33, wherein the patient in need thereof is human.


35. A compound represented by the formula:



for use in the treatment of a human coronavirus infection in a patient in need thereof.

36. The compound of claim 35, wherein the patient in need thereof is human.

~~37. A compound having the formula:~~



, wherein the compound is produced by a process comprising

a) reacting uridine having hydroxyl groups at positions 2', 3', and 5' with a protecting compound to protect the hydroxyl groups at positions 2' and 3' of uridine thereby forming a first intermediate;

b) esterifying the hydroxyl group at position 5' of the first intermediate to form an isobutyrate ester as a second intermediate;

c) reacting the second intermediate with a 1,2, 4 triazole compound followed by reaction with a hydroxylamine moiety at position 4, thereby forming a nucleoside-4-hydroxylamine-5′-ester; and

d) deprotecting the nucleoside-4-hydroxylamine-5′-ester to form the compound comprising uridine 4 hydroxylamine 5′ (2 methylpropanoate).

38. The compound according to claim 37, wherein the process comprises

a) reacting uridine having hydroxyl groups at positions 2', 3', and 5' with acetone to protect the hydroxyl groups at positions 2' and 3' of uridine thereby forming the first intermediate;


b) esterifying the hydroxyl group at position 5' of the first intermediate using 2-methylpropanoyl 2 methylpropanoate to form the isobutyrate ester as the second intermediate;

c) reacting the second intermediate with a 1,2,4 triazole compound followed by reaction with hydroxylamine at position 4 of the base, thereby forming the nucleoside-4-hydroxylamine 5′ ester; and

d) deprotecting the nucleoside 4 hydroxylamine 5′ ester at positions 2' and 3' to form the compound comprising uridine 4 hydroxylamine 5′ (2 methylpropanoate).

39. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound prepared by a process as recited in claim 37 or 38.

40. A process for preparing a compound having the formula:



„ comprising

a) reacting uridine having hydroxyl groups at positions 2', 3', and 5' with a protecting compound to protect the hydroxyl groups at positions 2' and 3' of uridine thereby forming a first intermediate;

b) esterifying the hydroxyl group at position 5' of the first intermediate to form an isobutyrate ester as a second intermediate;

c) reacting the second intermediate with a 1,2, 4-triazole compound followed by reaction with a hydroxylamine moiety at position 4, thereby forming a nucleoside-4-hydroxylamine-5′-ester; and

d) deprotecting the nucleoside 4 hydroxylamine 5′ ester to form the compound comprising uridine 4 hydroxylamine 5′ (2 methylpropanoate).

41. The process according to claim 40, comprising

a) reacting uridine having hydroxyl groups at positions 2', 3', and 5' with acetone to protect the hydroxyl groups at positions 2' and 3' of uridine thereby forming the first intermediate;

b) esterifying the hydroxyl group at position 5' of the first intermediate using 2-methylpropanoyl 2-methylpropanoate to form the isobutyrate ester as the second intermediate;

c) reacting the second intermediate with a 1,2,4-triazole compound followed by reaction with hydroxylamine at position 4 of the base, thereby forming the nucleoside 4-hydroxylamine 5′ ester; and

d) deprotecting the nucleoside 4 hydroxylamine 5′ ester at positions 2' and 3' to form the compound comprising uridine 4 hydroxylamine 5′ (2 methylpropanoate).